Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis.
about
Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsOne small step for a yeast--microevolution within macrophages renders Candida glabrata hypervirulent due to a single point mutationAntifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York COropharyngeal Candida colonization in human immunodeficiency virus infected patients.Sexually transmitted diseases treatment guidelines, 2015.Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?Mechanisms of antifungal drug resistance in Candida dubliniensis.Future therapies targeted towards eliminating Candida biofilms and associated infections.Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.Microbiological screening of Irish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy reveals persistence of Candida albicans strains, gradual reduction in susceptibility to azoles, and incidences of clinical signs of oral c
P2860
Q26863344-A43C5EFE-53A0-4EE4-9184-72348BB3A079Q27322886-12179374-DC33-4D86-87C4-0A1831B42E1CQ30452376-D9A97D90-8CE6-4D40-B05C-D1A28233614BQ30452998-BA3EA63F-9AAE-49A1-A3D7-86D5C9E87D90Q33887429-6304D5EB-CBEA-46CD-BA31-AA875857D2A8Q34131697-686CB118-20FC-46E7-9B41-75B9289091A2Q34144493-73109628-CC89-4EE6-9DDA-3BFCF4C13C3CQ34303424-6868D28F-C88B-412E-87BE-E7B1A1E8E3C9Q34479272-24053B81-1183-4F43-8AA3-2F56286F12EBQ34490092-A0E0A34F-E357-4E8D-8E7D-D911F6269785Q37762556-FC7F00F2-9985-454B-B342-09642590875EQ38786061-7200B457-CFF0-44C0-AAE4-8ECE5830C03EQ50700185-DC0BF386-1470-42A5-BA2A-80670C8C7D60Q58490188-F55263A9-CB31-4E8C-80B0-A5A2D03A1876
P2860
Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Evolution of antifungal suscep ...... iving fluconazole prophylaxis.
@en
Evolution of antifungal suscep ...... iving fluconazole prophylaxis.
@nl
type
label
Evolution of antifungal suscep ...... iving fluconazole prophylaxis.
@en
Evolution of antifungal suscep ...... iving fluconazole prophylaxis.
@nl
prefLabel
Evolution of antifungal suscep ...... iving fluconazole prophylaxis.
@en
Evolution of antifungal suscep ...... iving fluconazole prophylaxis.
@nl
P2093
P2860
P356
P1476
Evolution of antifungal suscep ...... iving fluconazole prophylaxis.
@en
P2093
Holloway W
Steele-Moore L
Vazquez JA
P2860
P304
P356
10.1086/322641
P407
P577
2001-09-05T00:00:00Z